Clinical trials
Phase 3 Retinal Vein Occlusion trials
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
46 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2002 | 1 |
| 2004 | 3 |
| 2005 | 1 |
| 2006 | 2 |
| 2007 | 4 |
| 2008 | 1 |
| 2009 | 5 |
| 2010 | 1 |
| 2011 | 4 |
| 2012 | 4 |
| 2013 | 2 |
| 2014 | 1 |
| 2016 | 2 |
| 2017 | 1 |
| 2018 | 1 |
| 2019 | 2 |
| 2020 | 4 |
| 2021 | 5 |
| 2022 | 1 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 35 |
| Terminated | 7 |
| Active, not recruiting | 2 |
| Unknown status | 2 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Novartis Pharmaceuticals | 10 |
| Allergan | 2 |
| Chengdu Kanghong Biotech Co., Ltd. | 2 |
| Clearside Biomedical, Inc. | 2 |
| Genentech, Inc. | 2 |
| Hoffmann-La Roche | 2 |
| National Eye Institute (NEI) | 2 |
| Outlook Therapeutics, Inc. | 2 |
| Regeneron Pharmaceuticals | 2 |
| The Emmes Company, LLC | 2 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Retinal Vein Occlusion | 46 |
| Macular Edema | 33 |
| Vision Disorders | 11 |
| Macular Degeneration | 3 |
| Wet Macular Degeneration | 3 |
| Edema | 2 |
| Retinal Diseases | 2 |
| Thrombosis | 2 |
| Choroidal Neovascularization | 1 |
| Eye Diseases | 1 |
Trials
Showing 51 to 46 of 46. Each trial links to its page on Pharma Observatory.
No trials match these filters.
Try a different keyword, or clear a filter.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.